2024 Annual Performance Report of Global Pharma Giants (Including 19 PPT Downloads)

Feb 08, 2025 09:30 CST Updated 09:30

Johnson & Johnson

Medical Device R&D and Manufacturer

As the 2024 financial reports are gradually released, the performance of pharmaceutical giants has once again become the focus of industry attention.This year, the "King of Drugs" K DrugGenerated Revenue of $29.482 Billion，In the face of strong opponents「Semaglutide」Faced with the ultimate life-saving option, Cilta-cel,Pluvicto Wait for newEmerging products are also constantly rising and breaking through. However, at the same time, with the approaching patent cliff, MNCs are resorting to various strategies, competing to lay out their future plans and seeking new points of performance growth.

This article will highlight the latest developments of pharmaceutical giants based on the 2024 performance of 13 TOP MNCs, for readers' reference only. Scan the QR code at the end of the article to download the 2024 financial reports PPT of major MNCs.

Overview of 2024 Performance of 13 Top MNCs (Unit: Billion USD)

Data Source: Insight Database

Johnson & Johnson:Daratumumab Revenue Breaks $10 Billion for the First Time

In 2024, Johnson & Johnson's revenue grew by 4.3% to USD 88.8 billion. By region, the United States remains Johnson & Johnson's primary market, generating USD 50.302 billion in revenue in 2024, an increase of 8.3% year-over-year; international market revenue was USD 38.519 billion.Pharmaceuticals remain the pillar sector of Johnson & Johnson, 2024Revenue of $56.964 billion，An increase of 5.7% year-on-year.

InterceptSource: Corporate earnings report (same below)

Johnson & Johnson Innovation Pharmaceuticals mainly focuses on oncology, neuroscience, infectious diseases, immunology, and pulmonary arterial hypertension.（PH）, Cardiovascular and Metabolic（CVM）In fields such as ..., performanceThe main growth drivers are Darzalex (daratumumab), Erleada (apalutamide), and Carvykti (ciltacabtagene autoleucel).Products in the field of oncology, as well as those in the field of immunologyTremfya (Guselkumab)And Neuroscience FieldSpravato (Esketamine)。

Among them,Daratumumab Annual Revenue of $11.67 Billion in China(An increase of 19.8% year-on-year), marking the first time that the drug's sales have exceeded $10 billion since its launch.. The BCMA CAR-T product co-developed with Legend BiotechCilta-cel Revenue $963 Million. Stelara (ustekinumab) in the immunology field and other products in the neuroscience sector performed poorly, offsetting some of the growth.

Merck: K Drug Remains the Pillar, Revenue of $29.5 Billion

In 2024, Merck's global revenue reached $64.2 billion, representing a 7% year-over-year increase. Of this, pharmaceutical business revenue was $57.4 billion, also reflecting a 7% growth. Merck anticipates that its revenue for 2025 will range between $64.1 billion and $65.6 billion.

In terms of product revenue,The pillar remains the star product PD-1 inhibitor Keytruda (Pembrolizumab), with sales increasing by 18% to $29.5 billion, contributing nearly 46% of Merck's revenue.However, another leading product, the HPV vaccine Gardasil/Gardasil 9, performed poorly, generating only $8.583 billion in revenue last year, a year-on-year decrease of 3%. Merck stated,This is mainly due to weak demand for HPV vaccines in the Chinese market.. In order to deplete inventory, Merck willSuspension of Quadrivalent HPV Vaccine Supply to ChinaGardasil，The nine-valent HPV vaccine continues to be shipped.

Among other products, those with relatively fast growth also includeHIF-2α Inhibitor Welireg (Belzutifan), with sales of $509 million, increasing by 133%. Approved for marketing in 2024(United States, European Union)ThePulmonary Arterial Hypertension Drug Winrevair (Sotatercept)Sales reached $419 million. In addition, the drug for preventing cytomegalovirus infectionPrevymis (Letermovir)Sales increased by 30% to USD 785 million,15-Valent Pneumococcal Vaccine VaxneuvanceSales increased by 22% to USD 808 million.

Pfizer: Revenue Growth Resumes in 2024, Income of $63.6 Billion

In 2023, Pfizer's total revenue declined due to fluctuations in the income from COVID-19 products.In 2024, Pfizer's revenue returned to growth, with a total annual income of $63.6 billion, representing a 7% year-over-year increase.; Excluding COVID products, growth was 12%. Pfizer forecasts revenue between $61 billion and $64 billion for 2025 and expressed confidence in its earnings report of returning to pre-pandemic operating profit margins in the coming years.

From the perspective of business segments,Primary Care Product Revenue: $30.135 Billion, Down 2% Year-over-YearAmong them, the anticoagulant drug Eliquis (apixaban) generated revenue of $7.366 billion (+9%), while the pneumonia vaccine Prevnar family brought in $6.411 billion (-1%).

Specialty Care revenue reached $16.652 billion, representing an 11% year-over-year increase.Among them, the revenue of Vyndaqel family, a rare disease drug containing chlorbenzazole, reached 5.451 billion US dollars, increasing by 64% year-on-year. The revenue of JAK inhibitor Xeljanz (tofacitinib) was 1.168 billion US dollars, decreasing by 31% year-on-year.

Oncology Business Revenue $15.612 Billion, Up 25% Year-on-YearAmong them, the revenue of CDK 4/6 inhibitor Ibrance (Palbociclib) was $4.367 billion, a year-on-year decrease of 8%. The revenue of androgen receptor inhibitor Xtandi (Enzalutamide) was $2.039 billion, a year-on-year increase of 23%. The revenue of PARP inhibitor Talzenna (Talazoparib) was $117 million, a year-on-year increase of 83%.

Novartis: China Market Becomes Key Driver

In 2024, NovartisAnnual Revenue of $50.317 Billion, representing a year-over-year increase of 12%. Among them,China Market Performance Shines, Revenue Reaches $3.9 Billion, an increase of 21% year-on-year, becoming one of the key factors driving Novartis' performance growth.

Novartis focuses on four core therapeutic areas, including Cardiovascular-Renal-Metabolism, Immunology, Neuroscience, and Oncology. In these areas, several blockbuster products have demonstrated strong growth momentum:

Novartis' Ace Product Entresto(Sacubitril Valsartan)Since its launch, sales have continued to grow, reaching $7.822 billion in 2024, a year-on-year increase of 31%.
Leqvio isWorld's First siRNA Ultra-Long-Acting Lipid-Lowering Drug, its sales achieved rapid growth in 2024, reaching 754 million US dollars, a year-on-year increase of 114%.
Pluvicto, the highly anticipated nuclear medicine, achieved sales of $1.392 billion in 2024, marking a 42% increase. Since its launch in 2022, this also represents the drug's sales performance.Exceeding 1 billion US dollars for the first time.

AbbVie: Surge in R&D Investment, Strong Performance in Autoimmune Drugs

In 2024, AbbVieTotal annual revenue of $56.334 billion，Investment in R&D fields at the same timeA significant year-on-year increase of 66.7%Reached 12.791 billion US dollars.

AbbVie's 3 Key Drugs in the Autoimmune Field Show Outstanding Performance:Skyrizi(Lisocabtagene Maraleucel)、Rinvoq(Upadacitinib)AndHumira(Adalimumab), respectively achievedSales of $11.718 billion, $5.971 billion, and $8.993 billion. Among them, SkyriziFollowing Humira to become the next$10 Billion Molecule。

From 2025 to 2026, AbbVie will achieve multiple regulatory approvals, submissions of marketing applications, and clinical data readouts for new drugs/indications. In its financial report, AbbVie reiterated that it expects to maintain a high single-digit compound annual revenue growth rate before 2029 and raised its forecast for the combined sales of Skyrizi and Rinvoq.More than 310 billion US dollars, while updating the outlook for the aesthetics business, with an expected high single-digit compound annual revenue growth rate from 2025 to 2029.

Sanofi: Dupixent Crowned as the "King of Autoimmune Drugs"

In 2024,SanofiAnnual revenue of 41.081 billion euros(Approximately USD 44.561 billion), an increase of 11.3% year-on-year. The total R&D investment for the year was 7.394 billion euros.(Approximately USD 8.02 billion), an increase of 14.6% year-on-year.

It is worth mentioning that the flagship product Dupixent(Dupilumab)Global sales reached in 2024$14.179 billion, a year-on-year increase of 23.1%, becomingNew Generation Autoimmunity「Medicine King」。In addition, Sanofi has a diversified pipeline of projects, such as Rilzabrutinib for immune thrombocytopenia and Isatuximab.（Sarclisa）For non-driver mutations in myeloma and mantle cell lymphoma, etc.

BMS: Up to 20Cut 2 billion US dollars cost at the end of 27 years

On February 6 local time, BMS released its 2024 financial report,Annual Revenue of $48.3 Billion(+7%), R&D investment of $11.59 billion (+20%).

Specifically, Opdivo (Nivolumab, PD1) and Yervoy (Ipilimumab, CTLA4) achieved sales of $9.304 billion (+3%) and $2.530 billion (+13%), respectively. Reblozyl (Luspatercept), Breyanzi, and Camzyos (Mavacamten) showed strong growth.The increase was over 50%.。

BMS disclosed in its financial report that the company will expand its strategic productivity plan,Achieve approximately $2 billion in cost savings by the end of 2027. This is a supplement to a restructuring measure introduced by BMS in April 2024, which planned to cut $1.5 billion in costs by the end of 2025, including layoffs of over 2,000 employees.

Lilly: The Birth of the First Super Blockbuster

WhenOn February 6 local time, Eli Lilly released its 2024 financial report.Annual Revenue of $450.43 Billion(+32%), including revenue from China of $1.66 billion (+9%). The strong growth in Eli Lilly's performance is mainly attributed to the replacementThe promotion of blockbuster products such as Tirzepatide (Mounjaro and Zepbound), Abemaciclib (Verzenio), Empagliflozin (Jardiance), and Ixekizumab (Taltz).

Among them, the phenomenal product Tirzepatide in 2024Successfully squeezed into the super blockbuster team, with sales reaching up to 16.466 billion US dollars. It also received FDA approval for the treatment of adult patients with moderate to severe obstructive sleep apnea (OSA) combined with obesity, indicating a considerable future growth potential. Abemaciclib, with an income of 5.3 billion US dollars, surpassed its rival Palbociclib for the first time, becoming the best-selling CDK4/6 inhibitor globally.

In 2025, Eli Lilly expects full-year revenueIncrease by 32%, willReceive 5 Regulatory ApprovalsIncluding Insulin efsitora alfa approved for type 2 diabetes, Orforglipron (oral GLP-1) approved for obesity, Tirzepatide approved for improving cardiovascular outcomes, and Pirtobrutinib approved for first-line treatment of chronic lymphocytic leukemia, among others.

Roche: Layout in Obesity Field Gradually Shows Results

Roche's Full-Year Revenue in 202460.495 billion Swiss francs(Approximately USD 68.892 billion, +7%), includingPharmaceutical Business Revenue: 46.171 Billion Swiss Francs(Approximately USD 52.58 billion, +8%). Total revenue in China was CHF 5.328 billion, pharmaceutical business CHF 2.926 billion (+6%), R&D investment CHF 13.042 billion (+1%).

Roche's best-performing products in the 2024 market are Ocrevus (ocrelizumab), Hemlibra (emicizumab), and Vabysmo (faricimab), with sales of 6.744 billion Swiss francs, 4.503 billion Swiss francs, and 3.864 billion Swiss francs, respectively. Among them, ocrelizumabIt is a multiple sclerosis drug that hasRanked No.1 for 4 consecutive years。

In 2025, Roche will have 7 indications receiving regulatory approvals, in addition to 19 key clinical data reads, includingGLP-1R/GIPR Dual Agonist CT-868(Once-daily subcutaneous injection) Phase II study data for the treatment of type 1 diabetes with obesity,Oral GLP-1R Agonist CT-996TreatmentPhase I Clinical Results of Type 2 Diabetes Mellitus with Obesity.

AstraZeneca: Revenue in China Hits Record High

On February 6 local time, AstraZeneca released its 2024 financial report for the full year.Revenue: $54.073 billion (+21%), including product sales of $50.938 billion (+19%).Revenue in China hit a record high, reaching $6.413 billion (+11%), accounting for 12% of total revenue.R&D investment of $13.583 billion, a year-on-year increase of 25%.For more details on AstraZeneca's 2024 financial report, seeClick the linkView。

GSK: Full-year revenue exceeds $40 billion, oncology drug sales double

In 2024,GlaxoSmithKline (GSK)Full-year revenue of 31.376 billion pounds (40.127 billion US dollars), an increase of 7% year-on-year.R&D investment of 6.401 billion pounds($8.186 billion), an increase of 5% year-on-year. More details about GSK's 2024 financial report are available.Click the linkView。

Novo Nordisk: "Semaglutide" Rakes in $293 Billion

2024 In the year, Novo Nordisk's global sales reached 290.4 billion Danish kroner, approximately $42.149 billion., increased by 26%。Among them,"Semaglutide" Sales Reach $29.296 Billion。Click the linkLearn more about Novo Nordisk's 2024 financial report.

Amgen: 21 Products Achieve Record-High Sales for the Year

On February 4 local time, Amgen announced its financial results, with total revenue for the full year 2024 increasing by 19% year-over-year to reach $33.4 billion, including Q4 total revenue rising 11% year-over-year to $9.1 billion. Excluding sales contributions from the acquisition of Horizon, revenue from other products grew by 7%, primarily driven by an 11% increase in sales volume.For more details on Amgen's 2024 financial report, seeClick the linkView。

Insight has collected 19 MNC 2024 Annual Report for Industry Reference,You can add Xiaoyin as a WeChat friend.Send "2024 Financial Report" to download.

Resource List

Cover Source:Zhan Kou Hai Luo

Disclaimer:This article is for information sharing only and does not represent the position or viewpoint of Insight. It does not recommend or introduce any treatment plans. If necessary, please consult and contact正规医疗机构.

Editor: ccai/Crescent/Xin Yao

PR Article Coordination: WeChat insightxb

SubmissionWeChat: insightxb; Email: insight@dxy.cn

Diversified functions, traceable data……

Insight Database Web Version Awaits Your Experience

Click to read the original text,ImmediatelyUnlock！